[Immunosuppressive therapy and tuberculosis].
Yoshikawa
Kosho
K
Yano
Shuichi
S
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D000995:Antitubercular Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D007371:Interferon-gamma; D007538:Isoniazid / Q000008:administration & dosage; D007564:Japan / Q000453:epidemiology; D008727:Methotrexate / Q000009:adverse effects; D012680:Sensitivity and Specificity; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D000069285:Infliximab; D007538:Isoniazid; D008727:Methotrexate